While this happened, Piper Sandler downgraded its ImmunityBio Inc [IBRX] rating to a Neutral from a an Overweight in a research note published on May 12, 2023; the price target was decreased to $4 from $10. A number of analysts have revised their coverage, including Jefferies’s analysts, who began to cover the stock in early August with a ‘”a Buy”‘ rating.
Price Performance Review of IBRX
On Tuesday, ImmunityBio Inc [NASDAQ:IBRX] saw its stock fall -1.09% to $2.73. Over the last five days, the stock has gained 1.87%. ImmunityBio Inc shares have risen nearly 6.64% since the year began. Nevertheless, the stocks have fallen -38.10% over the past one year. While a 52-week high of $10.53 was reached on 01/06/25, a 52-week low of $2.50 was recorded on 01/02/25. SMA at 50 days reached $4.27, while 200 days put it at $5.08.
Levels Of Support And Resistance For IBRX Stock
The 24-hour chart illustrates a support level at 2.64, which if violated will result in even more drops to 2.55. On the upside, there is a resistance level at 2.85. A further resistance level may holdings at 2.97. The Relative Strength Index (RSI) on the 14-day chart is 35.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.08, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 56.60%. Stochastics %K at 42.41% indicates the stock is a holding.
How much short interest is there in ImmunityBio Inc?
A steep rise in short interest was recorded in ImmunityBio Inc stocks on 2024-12-13, dropping by -7.64 million shares to a total of 44.41 million shares. Yahoo Finance data shows the prior-month short interest on 2024-11-15 was 52.05 million shares. There was a decline of -17.2%, which implies that there is a negative sentiment for the stock.
